JP2000516459A5 - - Google Patents

Download PDF

Info

Publication number
JP2000516459A5
JP2000516459A5 JP1998508844A JP50884498A JP2000516459A5 JP 2000516459 A5 JP2000516459 A5 JP 2000516459A5 JP 1998508844 A JP1998508844 A JP 1998508844A JP 50884498 A JP50884498 A JP 50884498A JP 2000516459 A5 JP2000516459 A5 JP 2000516459A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998508844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516459A (ja
JP4475683B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/012203 external-priority patent/WO1998004727A1/en
Publication of JP2000516459A publication Critical patent/JP2000516459A/ja
Publication of JP2000516459A5 publication Critical patent/JP2000516459A5/ja
Application granted granted Critical
Publication of JP4475683B2 publication Critical patent/JP4475683B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50884498A 1996-07-25 1997-07-15 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス Expired - Lifetime JP4475683B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68628096A 1996-07-25 1996-07-25
US08/686,280 1996-07-25
PCT/US1997/012203 WO1998004727A1 (en) 1996-07-25 1997-07-15 Recombinant pox virus for immunization against tumor-associated antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009171254A Division JP2009278997A (ja) 1996-07-25 2009-07-22 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス

Publications (3)

Publication Number Publication Date
JP2000516459A JP2000516459A (ja) 2000-12-12
JP2000516459A5 true JP2000516459A5 (Direct) 2005-03-10
JP4475683B2 JP4475683B2 (ja) 2010-06-09

Family

ID=24755674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50884498A Expired - Lifetime JP4475683B2 (ja) 1996-07-25 1997-07-15 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
JP2009171254A Pending JP2009278997A (ja) 1996-07-25 2009-07-22 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009171254A Pending JP2009278997A (ja) 1996-07-25 2009-07-22 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス

Country Status (6)

Country Link
US (1) US7410644B2 (Direct)
EP (2) EP0954593A1 (Direct)
JP (2) JP4475683B2 (Direct)
AU (1) AU731860B2 (Direct)
CA (1) CA2261989C (Direct)
WO (1) WO1998004727A1 (Direct)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
DE69924826T8 (de) * 1998-11-18 2008-09-25 Oxford Biomedica (Uk) Ltd. Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
CA2354024C (en) * 1998-12-09 2009-12-22 Jeffrey Schlom A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1865065A1 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1496939B1 (en) * 2002-04-09 2007-08-15 Sanofi Pasteur Limited Modified cea nucleic acid and expression vectors
JP2007502602A (ja) * 2003-08-21 2007-02-15 バイラックス・ディベロップメント・プロプライエタリー・リミテッド 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
US8933041B2 (en) 2003-11-12 2015-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services System for treating and preventing breast cancer
US8901093B2 (en) 2003-11-12 2014-12-02 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Custom vectors for treating and preventing pancreatic cancer
WO2010081766A1 (en) 2009-01-13 2010-07-22 Transgene Sa Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation
JP5379243B2 (ja) 2009-01-20 2013-12-25 トランジェーヌ、ソシエテ、アノニム 患者を選択するためのバイオマーカーおよびそれに関連する方法
JP5774578B2 (ja) 2009-03-24 2015-09-09 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
EP2419728B1 (en) 2009-04-17 2014-01-08 Transgene SA Biomarker for monitoring patients
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
AU2011285534B2 (en) 2010-08-06 2015-12-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
RU2714142C2 (ru) * 2013-11-05 2020-02-12 Бавариан Нордик А/С Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
CN106999577B (zh) 2014-07-16 2021-12-21 特兰斯吉恩股份有限公司 溶瘤病毒和免疫检查点调节因子组合
US20180028626A1 (en) 2015-02-13 2018-02-01 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
CA2990549A1 (en) 2015-07-31 2017-02-09 Bavarian Nordic A/S Promoters for enhancing expression in poxviruses
WO2017120204A2 (en) 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
US10822415B2 (en) 2016-01-28 2020-11-03 Inserm (Institut National De La Santéet De La Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
AU2017336269B2 (en) 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
US20190330655A1 (en) 2016-12-28 2019-10-31 Transgene Sa Oncolytic viruses and therapeutic molecules
US11203611B2 (en) 2017-04-14 2021-12-21 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
BR112020003669A2 (pt) 2017-08-24 2020-09-01 Bavarian Nordic A/S terapia de combinação para tratamento do câncer com administração intravenosa de um mva recombinante e de um anticorpo
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
US20220233607A1 (en) 2019-05-29 2022-07-28 Université De Tours Toxoplasma platform for treating cancer
KR20220162130A (ko) 2020-02-28 2022-12-07 탈락 테라퓨틱스, 인크. 트랜스글루타미나제-매개된 접합
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As Compositions improving poxvirus stability
CA3261778A1 (en) 2022-08-18 2024-02-22 Transgene CHIMERIC POXVIRUSES

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
AU674492B2 (en) * 1991-05-06 1997-01-02 United States of America, as represented by the Department of Health and Human Services, The Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
US5445953A (en) 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5374149A (en) 1993-01-13 1994-12-20 Computower Technologies, Corp. Vertical storage conveyor with symmetrical motor drive system
EP0789774A2 (en) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
EP0784483B1 (en) * 1994-10-03 2000-11-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)

Similar Documents

Publication Publication Date Title
JP2000512098A5 (Direct)
JP2000502280A5 (Direct)
JP2000501771A5 (Direct)
JP2000501599A5 (Direct)
JP2000501018A5 (Direct)
JP2000501324A5 (Direct)
JP2000504625A5 (Direct)
JP2000502472A5 (Direct)
JP2000501825A5 (Direct)
JP2000501338A5 (Direct)
JP2001503889A5 (Direct)
JP2000502485A5 (Direct)
JP2000502425A5 (Direct)
JP2000502568A5 (Direct)
JP2000501774A5 (Direct)
JP2000516459A5 (Direct)
JP2000500912A5 (Direct)
JP2000502570A5 (Direct)
JP2000514543A5 (Direct)
JP2000501876A5 (Direct)
JP2001503413A5 (Direct)
JP2000501744A5 (Direct)
JP2000514446A5 (Direct)
JP2000501229A5 (Direct)
JP2000502316A5 (Direct)